Table 3. Adverse events that occurred in at least two patients in stratum 2.

System organ class	Number (%) of patients
preferred term	PF-04523655 (μg)
	1000	1500	2250	3000	Total
	(N=3)	(N=3)	(N=3)	(N=18)	(N=27)
Number (%) of patients with at least 1 TEAE	1 (33.3)	3 (100)	1 (33.3)	14 (77.8)	19 (70.4)
Eye disorders
Choroidal neovascularization: study eye	0 (0)	0 (0)	0 (0)	2 (11.1)	2 (7.4)
Detachment of retinal pigment epithelium: study eye	0 (0)	1 (33.3)	0 (0)	2 (11.1)	3 (11.1)
Eye pain: study eye	0 (0)	0 (0)	0 (0)	2 (11.1)	2 (7.4)
Foreign body sensation in eyes: study eye	1 (33.3)	0 (0)	0 (0)	2 (11.1)	3 (11.1)
Gastrointestinal disorders
Nausea	0 (0)	0 (0)	0 (0)	2 (11.1)	2 (7.4)
Investigations
Intraocular pressure increased: study eye	0 (0)	0 (0)	0 (0)	2 (11.1)	2 (7.4)
Musculoskeletal and connective tissue disorders
Pain in extremity	1 (33.3)	0 (0)	0 (0)	1 (5.6)	2 (7.4)
Nervous system disorders
Headache	0 (0)	0 (0)	0 (0)	2 (11.1)	2 (7.4)